Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment

SAR405838 is a potent and specific MDM2 inhibitor currently being evaluated in Phase I clinical trials for the treatment of human cancer. Using the SJSA-1 osteosarcoma cell line which harbors an amplified MDM2 gene and wild-type p53, we have investigated the acquired resistance mechanisms both in vi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:PLoS One
Main Authors: Hoffman-Luca, C. Gianna, Yang, Chao-Yie, Lu, Jianfeng, Ziazadeh, Daniel, McEachern, Donna, Debussche, Laurent, Wang, Shaomeng
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2015
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4466389/
https://ncbi.nlm.nih.gov/pubmed/26070072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0128807
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki